BioNTech (BNTX) CCO awarded options and 10,069 performance share units

Rhea-AI Filing Summary

BioNTech SE Chief Commercial Officer Annemarie Hanekamp received new equity-based compensation awards. She was granted 10,069 performance share units and options on 12,586 ordinary shares, both with no upfront purchase price. The options have an exercise price of EUR 89.38 and may be settled in shares, ADSs, or cash at the supervisory board’s election. Both the options and PSUs vest in equal annual installments over four years starting on the first anniversary of the grant date and become exercisable four years after grant, subject to performance and service conditions.

Insights

Equity Compensation Analyst

Routine equity grants tie the CCO’s pay to long-term share performance.

The reporting person received 10,069 performance share units and options over 12,586 ordinary shares as compensation, rather than buying or selling stock in the market. The options carry an exercise price of EUR 89.38 per share.

Both awards vest annually over four years from the first anniversary of the grant date and become exercisable four years after grant, subject to performance and service conditions. PSUs depend on BioNTech’s share price versus the Nasdaq Biotechnology Index, aligning value with relative market performance.

The filing does not show any open-market trades, only new derivative awards. The economic impact for shareholders depends on future vesting, performance outcomes, and whether settlement occurs in shares, ADSs, or cash, as permitted under the plan.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hanekamp Annemarie

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	12,586	$0.00	--
Grant/Award	Performance Share Unit	10,069	$0.00	--

Holdings After Transaction: Option (right to buy) — 12,586 shares (Direct, null); Performance Share Unit — 10,069 shares (Direct, null)

Footnotes (1)

1. The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions. The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

Key Figures

Performance share units granted: 10,069 units Options granted: 12,586 options Option exercise price: EUR 89.38 per share +3 more

6 metrics

Performance share units granted 10,069 units Grant to Chief Commercial Officer on May 12, 2026

Options granted 12,586 options Grant to Chief Commercial Officer on May 12, 2026

Option exercise price EUR 89.38 per share Subject to adjustment cap relative to ADS price

ADS price cap 800% of grant-date price Cap on ADS trading price at exercise vs grant price

Vesting period 4 years Annual installments starting first anniversary of grant

Option expiration May 12, 2036 Expiration date for granted options

Key Terms

Performance Share Unit, American Depositary Share, Nasdaq Biotechnology Index, Option (right to buy), +1 more

5 terms

Performance Share Unit financial

"Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer"

A performance share unit (PSU) is a form of executive or employee pay that promises shares (or the cash value of shares) only if the company meets specific performance targets over a set period. Think of it like a bonus cheque that only arrives if the company hits agreed goals — it aligns managers’ rewards with business results and signals to investors how leadership is being incentivized to grow value over time.

American Depositary Share financial

"represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

Nasdaq Biotechnology Index financial

"based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index"

A stock index that tracks the performance of biotechnology companies listed on the NASDAQ stock exchange, combining many firms into a single measure of the sector’s movement. Think of it as a thermometer or basket that shows whether biotech stocks are generally rising or falling; investors use it to gauge sector health, compare individual holdings against the industry, and as the basis for funds that let you invest in the whole group at once.

Option (right to buy) financial

"The option may be settled in ordinary shares, ADSs and/or cash"

exercise price financial

"The exercise price of this option is EUR 89.38"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanekamp Annemarie

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(1)	05/12/2026		A		12,586		05/12/2030(2)	05/12/2036	Ordinary Shares(3)	12,586	$0	12,586	D
Performance Share Unit	$0	05/12/2026		A		10,069		05/12/2030(4)	05/12/2036	Ordinary Shares(4)	10,069	$0	10,069	D

Explanation of Responses:

1. The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.

2. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

3. The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.

4. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

Remarks:

	/s/ Humza Bokhari, Attorney-in-Fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did BioNTech (BNTX) grant to its Chief Commercial Officer?

BioNTech granted its Chief Commercial Officer 10,069 performance share units and options on 12,586 ordinary shares. These awards are compensation grants, not market purchases, and are tied to future vesting, performance conditions, and long-term service with the company.

What is the exercise price of the new BioNTech (BNTX) stock options?

The new options have an exercise price of EUR 89.38 per share. The exercise price may be adjusted so the trading price of an American Depositary Share on an exercise date does not exceed 800% of the grant-date exercise price, according to the filing footnote.

How do the BioNTech (BNTX) performance share units for the CCO vest and become exercisable?

Each performance share unit vests annually in equal installments over four years starting on the first anniversary of the grant date. They become exercisable four years after grant, subject to performance targets based on BioNTech’s share price versus the Nasdaq Biotechnology Index and continued service.

On what schedule do the new BioNTech (BNTX) stock options vest for the Chief Commercial Officer?

The options vest annually in equal installments over four years, beginning on the first anniversary of the grant date. They become exercisable four years after the grant date, provided specified performance-based and other conditions, including continued service, are satisfied under the company’s plan.

How can the new BioNTech (BNTX) options and performance share units be settled?

The options may be settled in ordinary shares, American Depositary Shares, and/or cash at the supervisory board’s election. Each performance share unit is economically equivalent to one ordinary share and may be settled in one ordinary share, one ADS, cash, or another form of equivalent economic value.

Do the BioNTech (BNTX) equity awards involve any open-market buying or selling by the CCO?

The filing shows grant or award acquisitions only, with no open-market buying or selling. Both transactions are coded as derivative awards (code A) and classified as acquisitions, meaning they are compensation grants rather than discretionary market trades in BioNTech shares or ADSs.